Go to Author Information Center
Revised December 20, 2021 | Revision history
The American Society for Clinical Investigation (ASCI) publishes the Journal of Clinical Investigation (JCI). The opinions expressed in the Journal are solely those of the authors and are not necessarily endorsed by the ASCI.
The JCI is a Gold Open Access journal in which all content is freely available wthout charge to the user or their institution. Effective with the January 4, 2022, issue, all content is published with a Creative Commons Attribution License (CC BY 4.0).
The ASCI retains copyright to many articles published in issues prior to January 4, 2022. While all content is freely available, some use of articles to which the ASCI holds copyright may require permission. (See “Obtaining permission to use JCI content” below.) Copyright or license information is noted on each article.
The JCI deposits all articles in PubMed and PubMed Central. Authors of articles published in the JCI do not need to deposit their articles separately. The Journal meets cOAlition S requirements for authors who receive funding support from Plan S signatories and is fully compliant with Howard Hughes Medical Institute (HHMI), Wellcome, and UK Research and Innovation (UKRI) open access policies; and is indexed in Securing a Hybrid Environment for Research Preservation and Acces (Sherpa Romeo).
Reprints can be obtained by contacting journal staff at email@example.com.
Beginning with the January 4, 2022, issue, articles are published with a CC BY 4.0 license, which allows for reuse without permission as long as the original source is cited. Permission may be required for use of content published in issues prior to January 4, 2022, where the ASCI retains copyright. Permission can be obtained via Copyright Clearance Center. Copyright or license information is noted on each article.
See the “Download citation information” link under “Article Tools” for each article for guidance on proper citation format. For example, see this citation page for the JCI article WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.
Use of JCI content constitutes an agreement to comply with the terms noted here. Any copies, in whole or in part, must include the associated license information or copyright notice.
In no event shall the JCI or the ASCI be liable for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with the use of or reliance on this information. This publication is provided “as is” without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Changes in policy or publication may be made at any time. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication.